Entyvio safe and effective for UC in real-world study

An analysis of data from the VICTORY consortium through the University of California at San Diego, as published in The American Journal of Gastroenterology, found vedolizumab effective in ulcerative colitis. Cumulative rates of endoscopic remission and clinical remission were the main effectiveness outcomes of the review. Researchers analyzed secondary outcomes measures of cumulative rates of

Biomarkers Associated with Response to Vedolizumab

Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD).  A recent study finds that pretreatment α4β7 expression and α4β7 receptor saturation during maintenance therapy were identified as candidate biomarkers for vedolizumab response. This assay leads to promise that we will be able to identify good candidates for biologic therapies